1. Home
  2. AIFU vs SPRO Comparison

AIFU vs SPRO Comparison

Compare AIFU & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIFU
  • SPRO
  • Stock Information
  • Founded
  • AIFU 1998
  • SPRO 2013
  • Country
  • AIFU China
  • SPRO United States
  • Employees
  • AIFU N/A
  • SPRO N/A
  • Industry
  • AIFU
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • AIFU
  • SPRO Health Care
  • Exchange
  • AIFU NYSE
  • SPRO Nasdaq
  • Market Cap
  • AIFU 61.0M
  • SPRO 49.6M
  • IPO Year
  • AIFU 2007
  • SPRO 2017
  • Fundamental
  • Price
  • AIFU $0.43
  • SPRO $0.87
  • Analyst Decision
  • AIFU
  • SPRO Buy
  • Analyst Count
  • AIFU 0
  • SPRO 4
  • Target Price
  • AIFU N/A
  • SPRO $5.00
  • AVG Volume (30 Days)
  • AIFU 1.5M
  • SPRO 262.1K
  • Earning Date
  • AIFU 03-18-2025
  • SPRO 03-12-2025
  • Dividend Yield
  • AIFU N/A
  • SPRO N/A
  • EPS Growth
  • AIFU N/A
  • SPRO N/A
  • EPS
  • AIFU 0.38
  • SPRO 0.06
  • Revenue
  • AIFU $324,923,970.00
  • SPRO $106,455,000.00
  • Revenue This Year
  • AIFU N/A
  • SPRO N/A
  • Revenue Next Year
  • AIFU $11.81
  • SPRO N/A
  • P/E Ratio
  • AIFU $1.14
  • SPRO $13.40
  • Revenue Growth
  • AIFU N/A
  • SPRO 37.01
  • 52 Week Low
  • AIFU $0.33
  • SPRO $0.83
  • 52 Week High
  • AIFU $6.59
  • SPRO $1.89
  • Technical
  • Relative Strength Index (RSI)
  • AIFU N/A
  • SPRO 35.29
  • Support Level
  • AIFU N/A
  • SPRO $0.86
  • Resistance Level
  • AIFU N/A
  • SPRO $0.94
  • Average True Range (ATR)
  • AIFU 0.00
  • SPRO 0.07
  • MACD
  • AIFU 0.00
  • SPRO -0.01
  • Stochastic Oscillator
  • AIFU 0.00
  • SPRO 12.57

About AIFU FANHUA INC SPON ADS EACH REPR 20 ORD SHS

AIX Inc is a technology-driven financial services provider company in China. It is an intelligent platform that creates a supportive and collaborative environment and provides solutions that integrate technology, products, services, operations, capital, and professional support for individual agents and sales organizations. The group uses technology, AI, and data-driven insights, pioneering the financial services that are delivered, its transformation, and empowering industry development. It connects customers with financial institutions, investment opportunities, and service providers, offering insurance, wealth management, and other value-added services.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: